Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1995 Feb;12(2):257-62.
doi: 10.1023/a:1016287128048.

Effect of norfloxacin on theophylline disposition: a comparison with other fluoroquinolones

Affiliations
Comparative Study

Effect of norfloxacin on theophylline disposition: a comparison with other fluoroquinolones

J D Davis et al. Pharm Res. 1995 Feb.

Abstract

The effects of norfloxacin (NOR), at steady-state plasma concentrations of 0-32 mg.l-1, on the plasma clearance of a 6 mg.kg-1 i.v. bolus dose of theophylline (THEO) in the male Sprague-Dawley rat have been studied. The effects were characterised by a Ki value (Ki = 12 microM), which was comparable with Ki values obtained previously under identical conditions for ciprofloxacin, but higher than that obtained for enoxacin. The distributional characteristics, volume of distribution and liver to plasma concentration ratio, were very similar for the three compounds. The only marked pharmacokinetic differences were in hepatic clearance, where there was a rank order NOR > ciprofloxacin > enoxacin, a reverse of the order in the reduction of THEO clearance seen in clinical studies. The advantages of using the steady-state experimental design described here are that equivalent concentrations are utilised to compare related drugs and differences in pharmacokinetics are accounted for, to allow a direct comparison of potency. This information, together with additional pharmacokinetic considerations, suggests that the different effects on THEO clearance seen in the clinic for NOR, ciprofloxacin and enoxacin are not solely due to differences in inhibitory potency, but also involve differences in hepatic clearance and hence systemic availability of the fluoroquinolones.

PubMed Disclaimer

References

    1. J Appl Physiol. 1974 Mar;36(3):391-2 - PubMed
    1. Clin Pharmacokinet. 1988 Sep;15(3):194-204 - PubMed
    1. Pharm Res. 1994 Oct;11(10):1424-8 - PubMed
    1. Clin Pharmacokinet. 1992 Mar;22(3):169-210 - PubMed
    1. Arzneimittelforschung. 1986 Oct;36(10):1496-502 - PubMed

Publication types